New drug duo aims to control aggressive lung and nerve cancers
NCT ID NCT04701307
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two drugs together for people with small cell lung cancer or other high-grade neuroendocrine cancers that have already been treated. Niraparib blocks a DNA repair protein in cancer cells, while dostarlimab helps the immune system attack the tumor. The goal is to see if the combination can shrink tumors or delay their growth. About 48 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Could a simple assessment help older lung cancer patients tolerate chemo better?
- Two-Drug combo aims to stall rare gut tumors